Clinical Trial Detail

NCT ID NCT02436707
Title Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors NCIC Clinical Trials Group
Indications

diffuse large B-cell lymphoma

B-cell lymphoma

Therapies

Ibrutinib

Cisplatin + Dexamethasone + Gemcitabine + Rituximab

Age Groups: adult

No variant requirements are available.